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Mayer Point/CounterpointTranscatheter aortic valve implantation should be controlled and
monitored by the medical professionJohn E. Mayer, Jr, MDOn the basis of the accompanying case presentation of
a 75-year-old widowed male nursing home resident with
hemodynamically significant aortic stenosis, heart failure,
angina, and a high surgical risk for a conventional aortic
valve replacement, I support the proposition that the newly
emerging transcatheter aortic valve implantation (TAVI)
should be ‘‘rationed,’’ or at least monitored and controlled.
The Placement of AoRTic TraNscathetER Valve (PART-
NER) trial assessed both the clinical outcomes and re-
source use results from this multicenter prospective,
randomized trial of transcatheter aortic valve insertion in
both patients at ‘‘high risk’’ for open heart aortic valve re-
placement and in surgically ‘‘inoperable’’ patients. The re-
sults of the trial indicated that in surgically inoperable
patients receiving a transcatheter aortic valve compared
with ‘‘medically treated’’ patients (most with balloon val-
votomy alone), the 1-year mortality for patients undergoing
TAVI was 30.7% versus 50.4% for ‘‘medically treated’’
patients. The stroke rate was 5% in the patients undergoing
TAVI versus 1.1% in the medical group, and the major vas-
cular complication rates were 16.2% versus 1.1% for
TAVI and medically treated patients, respectively.1 The av-
erage total cost for the TAVI procedure itself was $46,238,
and the average total hospitalization cost for the admission
at which TAVI was performed was $78,540. The 1-year av-
erage resource use after the TAVI admission was $29,352
versus $52,724 for those treated medically. The study
showed that this therapy added on average 1.59 incremen-
tal life years at a cost of $50,212 per added life year. The
increment in quality-adjusted life years was 1.29 years at
a cost of $61,889 per added quality-adjusted life year.2
For this patient, my recommendation regarding the use of
TAVI would rest on an assessment of his ‘‘frailty’’ and
the presence of other comorbidities that would exert the
dominant impact on his survival and quality of life. Being
a widower and living in a nursing home alone do not rep-
resent sufficient comorbid conditions to preclude
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the diffusion of this technology should be carefully moni-
tored and controlled by the medical profession. Some
may argue that ‘‘monitoring and control’’ is a distinction
without a difference from ‘‘rationing,’’ but uncontrolled dif-
fusion of new medical technology has been a major source
of the current crisis in funding for medical care in the
United States,3 with approximately 18% of the gross do-
mestic product now devoted to health care.4 Given the
growing elderly population in this country and the inci-
dence of aortic valve sclerosis in this aging population,
there is a significant likelihood that use of TAVI for all el-
derly patients with aortic valve disease could add signifi-
cantly to the Medicare expenditures for cardiovascular
disease.
I5 and others6,7 have argued that it is a responsibility of
the medical profession to wisely allocate societal health
care resources, but if TAVI results in improved 1-year
survival, how could an ethical physician or surgeon, or an
entire society ‘‘deny’’ a given individual patient access to
this technology. Consideration of this dilemma reveals
some fundamental conflicts both within the value
structures of the medical profession and within the value
structures of American society, which I will attempt to
briefly describe. I will then offer my own thoughts on
how to address some of these dilemmas.
As a starting point, it is important to distinguish between
efficacy and effectiveness. Assessment of the efficacy and
safety of medical devices is the province of the US Food
and Drug Administration, which is tasked with determining
whether a new device safely accomplishes the stated pur-
pose of the device. This efficacy assessment is typically
based on randomized clinical trials, such as the PARTNER
trial, in carefully defined clinical populations. Effectiveness
has been described as the outcome when this same device is
deployed in the general population by the medical profes-
sion. The Food and Drug Administration does not have
(or want) the legal mandate to regulate the practice of med-
icine, and thus the assessment of the effectiveness of a de-
vice has traditionally been the responsibility of the
medical profession, although health services researchers in-
creasingly have inserted themselves into this domain. The
assessments of effectiveness involve the medical profes-
sion’s obligations to society to self-regulate and to wisely
allocate what is now becoming a scarce societal resource.
I have argued that if the medical profession does not ac-
tively engage in this effectiveness assessment, then major
resource allocation decisions will be made by those whordiovascular Surgery c Volume 143, Number 4 771
Point/Counterpoint Mayerdo not take care of patients, and then the medical profession
will have forfeited an important role and responsibility in
American society.5,8 Krause, in Death of the Guilds,9 has
pointed out that professions are granted privileges and pre-
rogatives by a society only so long as society believes that
the profession is acting in the society’s interest and not in
its own interest. In the context of other erosions of medi-
cine’s prerogatives and privileges that have occurred in re-
cent years, including managed care constraints on
diagnostic testing, medication use, and procedures, I be-
lieve that failure to address the effectiveness question by
the profession, even if it means that professional income
will suffer, will be a major mistake that will affect the ability
of medicine to continue to function as a profession.
The overriding issue for this debate, however, is reconcil-
iation of the 2 roles that physicians have: ‘‘healer of the
sick’’ and ‘‘member of a profession.’’5,6 These 2 roles
have different historical roots and can potentially come
into conflict,6 as in the case that served as the topic for
this debate. Should a ‘‘healer of the sick’’ choose not to of-
fer a potentially beneficial therapy to any patient? Should
a member of a profession disregard the profession’s respon-
sibilities to the society that it serves by failing to
self-regulate or towisely allocate societal resources? If phy-
sicians and surgeons indiscriminately apply a new and ex-
pensive technology to any patient who might benefit, even
if it will minimally prolong life or marginally reduce suffer-
ing, can the medical profession argue that there has been
a wise use of society’s health care dollar? Is there a means
by which both of these responsibilities of the physician can
be fulfilled? I submit that there is, and I believe that the so-
lution to this dilemma must rest on a rigorous, controlled
collection and analysis of data on both the clinical and the
resource use outcomes for this transcatheter valve therapy.
I submit that outcomes data have the greatest impact on
physician practice, and these outcomes must include both
clinical outcomes and resource use outcomes for the proce-
dure itself and for at least several years after the procedure. I
believe that this approach will, of necessity, require a con-
trolled dissemination of this technology and linkage of clin-
ical databases with administrative claims databases so that
resource use over time can be assessed after device inser-
tion. The presidents of the Society of Thoracic Surgeons
and American College of Cardiology have published a joint
position paper on transcatheter aortic valve technology in
which these 2 professional societies advocate many ele-
ments of such an approach, including recommendations
for a multidisciplinary team approach, specific require-
ments regarding facility resources, specific standardized
protocols for management strategies, procedural perfor-
mance, problem solving, and complication management,
and the development of clinical databases and registries to
evaluate practice patterns, treatment outcomes, and com-
parative effectiveness.10 The ASCERT (American College772 The Journal of Thoracic and Cardiovascular Surgof Cardiology Foundation–The Society of Thoracic Sur-
geons Collaboration on the Comparative Effectiveness of
Revascularization Strategies) study, in which I have been
privileged to serve as a co-investigator, attempts to compare
coronary bypass surgery with percutaneous coronary inter-
ventions and has used the Society of Thoracic Surgeons’
Adult Cardiac Database and the American College of Car-
diology interventional catheterization database with linkage
of both databases to the Medicare claims database. This
study has demonstrated that such database linkages can be
accomplished and that long-term outcomes, including re-
source use, can be assessed through linkage of these data-
sets. We cannot ignore the simple notion that value equals
quality divided by cost, and society must ultimately believe
that the deployment of its resources is providing real value
to its members and not just to the profession that provides
the services.
It is my expectation that the information from an ongoing
study of TAVI will provide direction to cardiologists and
surgeons involved in this therapy to identify subgroups of
patients for whom this therapy will provide little benefit
and could result in significant harm, particularly neurologic
injury. In addition, it will be critical that the patients be pro-
vided this information so that each may make his or her own
decision. It is this type of rigorously collected and analyzed
information that will provide a pathway through the di-
lemma posed by the coexisting roles of healer of the sick
and member of a profession that must wisely allocate soci-
etal resources. I anticipate that the patient characteristics
that will indicate little benefit from TAVI will be in the
realm of noncardiac comorbidities and ‘‘frailty.’’ There
will always be differences of professional opinion in a given
case, but the information on the outcomes and effectiveness
of any therapy will enable physicians, surgeons, and pa-
tients to make the wisest choices both for the patient and
for society to ensure that both patient and society recognize
the value of the therapy.
It is for these reasons that I believe the diffusion of the
transcatheter aortic valve replacement technology should
be controlled and monitored by the profession. I believe
that such a process is distinctly different from ‘‘rationing,’’
particularly because rationing implies that the process
would be carried out by an entity that is not directly in-
volved in the interaction between patient and physician. If
physicians, surgeons, and patients can rationally assess rig-
orously collected and analyzed information, then I am con-
fident that the profession can be true to its responsibilities to
both patients and society, and we in the profession can make
the right recommendations to our patients regarding the ap-
plication of this new technology. In so doing, we and our pa-
tients will be able to limit the application of this new
technology to those who will best benefit by it and spare so-
ciety, through its governmental representatives, from mak-
ing ill-advised, blanket judgments about the wisdom ofery c April 2012
Mayer Point/Counterpointapplying TAVI to individual patients or to an entire
population.
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